Press release
Non-Alcoholic Fatty Liver Disease Pipeline Analysis 2025 by DelveInsight | Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma
DelveInsight's, "Non-Alcoholic Fatty Liver Disease - Pipeline Insight, 2025" report provides comprehensive insights about 90+ companies and 100+ pipeline drugs in Non-Alcoholic Fatty Liver Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.DelveInsight reports that the Non-Alcoholic Fatty Liver Disease (NAFLD) pipeline features 90+ prominent companies actively developing over 100 treatment therapies.
Non-Alcoholic Fatty Liver Disease Overview:
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver disorders marked by the accumulation of fat within liver cells (macrovesicular steatosis), detected through imaging or biopsy, without other identifiable causes such as excessive alcohol intake, prolonged use of liver-toxic medications, or genetic conditions. In Western countries, NAFLD affects about 20-30% of the population.
The condition is strongly associated with risk factors including obesity, type 2 diabetes, dyslipidemia, insulin resistance, and metabolic syndrome. Research has also indicated a potential link between exposure to inorganic arsenic and NAFLD, evidenced by elevated alanine aminotransferase (ALT) levels. Since NAFLD is closely connected to metabolic syndrome, it often coexists with cardiovascular risk factors. Along with the possibility of progressing to cirrhosis and hepatocellular carcinoma, these complications significantly contribute to mortality in affected patients.
Download our report @ https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Non-Alcoholic Fatty Liver Disease Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Non-Alcoholic Fatty Liver Disease Therapeutics Market.
Key Takeaways from the Non-Alcoholic Fatty Liver Disease Pipeline Report
*
DelveInsight's report on the Non-Alcoholic Fatty Liver Disease (NAFLD) pipeline highlights a dynamic landscape, with more than 90 companies actively developing over 100 therapeutic candidates.
*
In March 2024, the U.S. FDA granted accelerated approval to Rezdiffra (resmetirom) for adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis. This landmark decision made Rezdiffra the first approved treatment specifically for NASH, also referred to as metabolic dysfunction-associated steatohepatitis (MASH).
*
Leading companies driving innovation in this space include Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel, Inventiva Pharma, Galectin Therapeutics, AngioLab, MediciNova, AstraZeneca, among others.
*
Noteworthy therapies currently in various phases of development include Lanifibranor, ZED 1227, TVB-2640, ALS-L1023, AZD9550, and additional promising candidates.
Non-Alcoholic Fatty Liver Disease Pipeline Analysis
The Non-Alcoholic Fatty Liver Disease pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Non-Alcoholic Fatty Liver Disease Market.
*
Categorizes Non-Alcoholic Fatty Liver Disease therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Non-Alcoholic Fatty Liver Disease drugs under development based on:
*
Stage of development
*
Non-Alcoholic Fatty Liver Disease Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Non-Alcoholic Fatty Liver Disease Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Non-Alcoholic Fatty Liver Disease Licensing agreements
*
Funding and investment activities supporting future Non-Alcoholic Fatty Liver Disease market advancement.
Request for a sample report @ https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Non-Alcoholic Fatty Liver Disease Emerging Drugs
*
Lanifibranor: Inventiva Pharma
*
ZED 1227: Dr. Falk Pharma GmbH
*
TVB-2640: Sagimet Biosciences
*
ALS-L1023: AngioLab
*
AZD9550: AstraZeneca
Non-Alcoholic Fatty Liver Disease Companies
Nearly 90 prominent companies are engaged in developing therapies for Non-Alcoholic Fatty Liver Disease (NAFLD), with Inventiva Pharma advancing one of its drug candidates to the most advanced stage-Phase III clinical trials.
DelveInsight's report covers around 100+ products under different phases of Non-Alcoholic Fatty Liver Disease clinical trials like
*
Non-Alcoholic Fatty Liver Disease Late stage Therapies (Phase III)
*
Non-Alcoholic Fatty Liver Disease Mid-stage Therapies (Phase II)
*
Non-Alcoholic Fatty Liver Disease Early-stage Therapies (Phase I)
*
Non-Alcoholic Fatty Liver Disease Pre-clinical and Non-Alcoholic Fatty Liver Disease Discovery stage Therapies
*
Non-Alcoholic Fatty Liver Disease Discontinued & Inactive Therapies
Non-Alcoholic Fatty Liver Disease pipeline report provides the Non-Alcoholic Fatty Liver Disease therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Non-Alcoholic Fatty Liver Disease Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Non-Alcoholic Fatty Liver Disease Therapies and Key Non-Alcoholic Fatty Liver Disease Companies: Non-Alcoholic Fatty Liver Disease Clinical Trials and recent advancements [https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Non-Alcoholic Fatty Liver Disease Pipeline Therapeutic Assessment
- Non-Alcoholic Fatty Liver Disease Assessment by Product Type
- Non-Alcoholic Fatty Liver Disease By Stage
- Non-Alcoholic Fatty Liver Disease Assessment by Route of Administration
- Non-Alcoholic Fatty Liver Disease Assessment by Molecule Type
Download Non-Alcoholic Fatty Liver Disease Sample report to know in detail about the Non-Alcoholic Fatty Liver Disease treatment market @ Non-Alcoholic Fatty Liver Disease Therapeutic Assessment [https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Non-Alcoholic Fatty Liver Disease Current Treatment Patterns
4. Non-Alcoholic Fatty Liver Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Non-Alcoholic Fatty Liver Disease Late-Stage Products (Phase-III)
7. Non-Alcoholic Fatty Liver Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Non-Alcoholic Fatty Liver Disease Discontinued Products
13. Non-Alcoholic Fatty Liver Disease Product Profiles
14. Non-Alcoholic Fatty Liver Disease Key Companies
15. Non-Alcoholic Fatty Liver Disease Key Products
16. Dormant and Discontinued Products
17. Non-Alcoholic Fatty Liver Disease Unmet Needs
18. Non-Alcoholic Fatty Liver Disease Future Perspectives
19. Non-Alcoholic Fatty Liver Disease Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Non-Alcoholic Fatty Liver Disease Pipeline Reports Offerings [https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nonalcoholic-fatty-liver-disease-pipeline-analysis-2025-by-delveinsight-guangdong-raynovent-biotech-dr-falk-pharma-gmbh-enyo-pharma-viking-therapeutics-sagimet-biosciences-terns-sinew-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-Alcoholic Fatty Liver Disease Pipeline Analysis 2025 by DelveInsight | Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma here
News-ID: 4165681 • Views: …
More Releases from ABNewswire

Phenix City Medical Practice Announces Expanded Healthcare Services, Addressing …
Preferred Medical Group, Phenix City, announces the expansion of its healthcare services and improved patient access, addressing community demand for comprehensive medical care with integrated pediatric, adult, and therapeutic services under one roof.
Preferred Medical Group, Phenix City [https://preferredmedgroup.com/], has announced significant enhancements to its healthcare services, responding to increased community demand for accessible and comprehensive medical care. The medical practice, located at 3700 South Railroad Street, has introduced streamlined patient…

Auburn Medical Practice Expands Integrated Care Model as Primary Care Doctor Add …
Preferred Medical Group - Auburn expands ADHD services and integrated care model, offering comprehensive family medicine, behavioral health, and specialized attention disorder treatment in one convenient East Alabama location.
Preferred Medical Group - Auburn [https://preferredmedgroup.com/] has announced significant enhancements to its integrated healthcare services, responding to increased demand for ADHD treatment and comprehensive family medical care in East Alabama. The Auburn location, situated at 318 Samford Village Court, Suite 100, now…

Local ADHD Doctor Program Launches at Preferred Medical Group - Opelika for East …
Preferred Medical Group - Opelika launches an integrated ADHD treatment program that combines pediatric care, psychiatry, and therapy services to address regional healthcare needs for East Alabama families.
Opelika healthcare providers have taken a significant step toward addressing the growing need for specialized attention deficit hyperactivity disorder services in East Alabama. Preferred Medical Group - Opelika [https://preferredmedgroup.com/] has announced the expansion of comprehensive ADHD treatment programs, integrating pediatric care with behavioral…

Prominent Criminal Lawyer in Galveston Firm Celebrates 25+ Years of Texas Gulf C …
Tad Nelson & Associates celebrates over 25 years of criminal defense excellence across the Texas Gulf Coast, combining local roots, community involvement, and personalized legal services that span multiple counties.
A prominent Texas law firm has reached a significant milestone, celebrating over 25 years of providing criminal defense and family law services across the Greater Houston area and Galveston County. The achievement underscores the firm's steadfast commitment to serving Texas communities…
More Releases for Fatty
Dimeric fatty acid Market, Dimeric fatty acid Market Growth, Dimeric fatty acid …
The Fact.MR report covers all the recent developments in the dimeric fatty acid market. The report features a list of market leaders and new entrants in the dimeric fatty acid market, including Croda International Plc., Kraton Corporation, Oleon NV, Shandong Huijin Chemical Co. Ltd., Liancheng Baixin Science and Technology Co. Ltd., Jiangsu Jinma Oil Technology Development Co., Ltd., Jiangsu Yonglin Oleochemical Co. Ltd., Anqing Hongyu Chemical Co., Ltd., Aturex Group,…
Oleochemical Fatty Acids Markets to 2022 | Stearic acid, Distilled fatty acids, …
Researchmoz added Most up-to-date research on "Oleochemical Fatty Acids: Global Markets to 2022" to its huge collection of research reports.
The global market for natural fatty acids reached $12.1 billion in 2016. The market should reach $12.8 billion in 2017 and $16.8 billion by 2022, increasing at a compound annual growth rate (CAGR) of 5.6% from 2017 through 2022.
To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1384171
Report Includes
…
Future Trends of Fatty Amines Market
Future Market Insights (FMI) announces the release of its latest report titled, “Fatty Amines Market: Global Industry Analysis and Opportunity Assessment 2015-2020”. According to the report, the global fatty amines market was valued at US$ 1,721 Mn in 2014 and is anticipated to reach US$ 2,193 Mn by 2020, registering a compound annual growth rate (CAGR) of 4.2% through the forecast period.
Fatty Amines Market Driven by Booming Water Treatment Chemicals…
Coconut Fatty Acids Market Report 2018: Segmentation by Product (Whole Coconut F …
Global Coconut Fatty Acids market research report provides company profile for Vantage Specialty Chemicals, Inc., Pacific Oleochemicals Sdn Bhd, Emery Oleochemicals, Chemical Associates, Inc., Echo Chem Pacific Sdn. Bhd., United Coconut Chemicals, Inc., Guangzhou Hangsheng Chemical Industry Co., Ltd., Osky Integrated, Timur Oleochemicals Malaysia, Twin Rivers Technologies, Inc. and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to…
Natural Fatty Acids Market Research Report
This report studies the global Natural Fatty Acids market status and forecast, categorizes the global Natural Fatty Acids market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia).
Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-natural-fatty-acids-2018-991
The major manufacturers covered in this report
BASF SE
Akzo Nobel.
Ashland
Croda
Eastman
Arizona Chemicals
Chiba Fatty Acid Co. Ltd.
Baerlocher GmbH
Chemithon Corporation
Behn-Meyer…
Global Oleochemicals Market: By Type - Fatty Acid, Fatty Alcohol, Glycerine
Latest industry research report on: Global Oleochemicals Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts
Driven by the rise in the consumption of bio degradable products among the growing population due to high purchasing power combined with environmental safety has led to the growth in the demand of oleochemicals market globally.
Request For Sample Report @
http://www.marketresearchreports.biz/sample/sample/739551
Oleochemicals are used to reduce toxic content of product. These…